



Extension of the Postponement of the Settlement

of the public tender offer by

CSL Behring AG, Berne, Switzerland

for all publicly held registered shares with a nominal value of CHF 0.01 each of

Vifor Pharma Ltd., St. Gallen, Switzerland

On January 18, 2022, CSL Behring AG (the **Offeror**) published the offer prospectus (the **Offer Prospectus**) for its public tender offer according to articles 125 *et seq.* FMIA (the **Offer**) for all publicly held registered shares of Vifor Pharma Ltd. (**Vifor**) with a nominal value of CHF 0.01 each (each a **Vifor Share**). The offer price for each Vifor Share is USD 179.25 in cash, less the gross amount of any dilutive effects in respect of the Vifor Shares prior to the Settlement (as further described in the Offer Prospectus).

Terms not defined herein have the meaning assigned to them in the Offer Prospectus.

Extension of the Postponement of the Settlement, Offer Conditions and Settlement Date

In the definitive notice of the end result dated March 28, 2022, the Offeror declared a Postponement of the Settlement pursuant to Section B.7(3) (*Period With Respect to Which the Offer Conditions are in Effect*) of the Offer Prospectus, and the Settlement has therefore been postponed for a period of up to four (4) months after the expiration of the Additional Acceptance Period, *i.e.* until July 22, 2022.

The Offer Condition pursuant to Section B.7(1)(b) (*Merger Clearances, Foreign Direct Investment and Other Approvals*) of the Offer Prospectus is not expected to be fulfilled by July 22, 2022. The Offeror has therefore submitted a request to the Takeover Board (the **TOB**) for approval of a Postponement of the Settlement until September 30, 2022. The TOB has approved this request by decision (*Verfügung*) dated July 12, 2022 as follows (unofficial translation of the German original):

- "1. CSL Behring AG is allowed to postpone the settlement of the public tender offer for all publicly held registered shares of Vifor Pharma Ltd. until September 30, 2022.
2. CSL Behring AG must inform the public about the extension of this postponement of the settlement in accordance with articles 6 and 7 TOO. The publication shall contain the conclusions of the present decision.
3. The present decision will be published on the website of the Takeover Board after its publication in accordance with conclusion number 2.
4. The fee payable by CSL Behring AG and CSL Limited under joint and several liability amounts to CHF 20,000."

Based thereon, the Offeror declares a further Postponement of the Settlement until September 30, 2022.

The Offer and the Settlement remain subject to the satisfaction of the Offer Conditions pursuant to Section B.7(1)(b), Section B.7(1)(c), Section B.7(1)(e), Section B.7(1)(g) and Section B.7(1)(h) of the Offer Prospectus.

The Offeror will announce the Settlement Date after the satisfaction or waiver of all of the Offer Conditions mentioned above that remain in effect.

Delisting, Exemption from Disclosure and Publicity Obligations, Squeeze-out

As described in the Offer Prospectus, the Offeror intends to have Vifor submit an application to SIX Exchange Regulation AG for the delisting of the Vifor Shares. Vifor has submitted a request to SIX Exchange Regulation AG on July 7, 2022, for an exemption from certain disclosure and publicity obligations until the date of delisting of the Vifor Shares.

The Offeror has filed an action with the Commercial Court of St. Gallen on May 31, 2022, requesting the cancellation of the remaining publicly held Vifor Shares in accordance with article 137 FMIA. The proceedings are suspended until the Settlement of the Offer and will be resumed after the Settlement.

Cf. in this regard Section E.3 (*Intentions of Offeror with Respect to Vifor*) and Section K.7 (*Cancellation, Squeeze-out Merger and Delisting*) of the Offer Prospectus.

Offer Restrictions

The Offer is subject to the offer restrictions as set forth in the Offer Prospectus. The Offer Prospectus may be obtained free of charge in German, French and English from Credit Suisse AG (e-mail: equity.prospectus@credit-suisse.com). The Offer Prospectus and other information concerning the Offer are also available at www.csltransaction.com.

Vifor Pharma Ltd.	Swiss securities number	ISIN	Ticker symbol
Vifor Shares not tendered (first trading line)	36 474 934	CH036 474 934 8	VIFN
Vifor Shares tendered (second trading line)	115 606 016	CH115 606 016 7	VIFNE
Vifor Shares tendered for USD/CHF Conversion Facility (third line, not traded)	115 606 017	CH115 606 017 5	--

July 13, 2022

Lead Financial Advisor
PJT Partners

Financial Advisor
BofA SECURITIES

Financial Advisor
Goldman Sachs

Financial Advisor and Offer Manager
Credit Suisse